News

Wednesday June 5, 2019

04 Jun 2019 – Result of AGM

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Result of Annual General Meeting Brighton, United Kingdom – 4 June 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company […]

Wednesday June 5, 2019

20 May 2019 – Destiny Pharma are part of the UK government Global Expert Mission d...

Destiny Pharma is part of the UKRI, InnovateUK and Knowledge Transfer Network’s Global Expert Mission delegation to Germany on Anti-Microbial Resistance, 20 – 24 May 2019. To find out more […]

Wednesday June 5, 2019

09 May 2019 – Pharmafocus publish article “The global rise in antibiotic res...

“Dr Bill Love, Founder and Chief Scientific Officer of Destiny Pharma, discusses the rise of antimicrobial resistance (AMR), the antibiotic stewardship required to offset this global threat, and the additional […]

Wednesday June 5, 2019

09 May 2019 – Destiny Pharma appoints NOMAD and Joint Broker

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Appointment of NOMAD and Joint Broker Brighton, United Kingdom – 9 May 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology […]

Wednesday June 5, 2019

02 May 2019 – Destiny Pharma welcomes United Nations report

Destiny Pharma welcomes a United Nations report calling for immediate, coordinated and ambitious action to avert a potentially disastrous drug-resistance crisis Destiny Pharma’s XF drug platform is well positioned to […]

Wednesday June 5, 2019

29 Apr 2019 – Posting of Accounts and Notice of AGM

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Posting of Annual Report and Accounts, and Notice of AGM Brighton, United Kingdom – 29 April 2019 – Destiny Pharma (AIM: DEST), […]